Quince Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense in USD from Q1 2019 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Quince Therapeutics, Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from Q1 2019 to Q2 2024.
  • Quince Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending June 30, 2024 was $1.22M, a 1123% increase year-over-year.
  • Quince Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending June 30, 2024 was $1.02M.
  • Quince Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $100K, a 99.4% decline from 2022.
  • Quince Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $16.6M, a 44.3% decline from 2021.
  • Quince Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2021 was $29.9M, a 106% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $1.02M $1.22M +$1.12M +1123% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-13
Q1 2024 -$107K $1.27M -$207K -14% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-13
Q4 2023 $100K -$2.81M -$4.45M -272% Oct 1, 2023 Dec 31, 2023 10-Q 2024-08-13
Q3 2023 $4.55M $1.33M +$637K +91.8% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $100K -$4.95M -98% Aug 4, 2023 10-Q 2024-05-13
Q2 2023 $3.91M $1.32M -$3.73M -73.8% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-13
Q1 2023 $8.86M $1.48M -$7.76M -84% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-13
Q4 2022 $16.6M $1.63M -$6.86M -80.8% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-01
Q3 2022 $23.5M $694K -$6.92M -90.9% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $30.4M $5.05M -$1.7M -25.2% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-03
Q1 2022 $32.1M $9.24M +$2.25M +32.2% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-15
Q4 2021 $29.9M $8.49M +$3.54M +71.3% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-15
Q3 2021 $26.3M $7.62M +$3.46M +83.2% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $22.9M $6.75M +$3.35M +98.6% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $19.5M $6.99M +$5.04M +258% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $14.5M $4.96M +$4.38M +759% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-01
Q3 2020 $10.1M $4.16M +$3.25M +356% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-29
Q2 2020 $6.84M $3.4M +$3.02M +801% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-06
Q1 2020 $3.82M $1.96M +$1.77M +929% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 $2.06M $577K Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 $912K Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-12
Q2 2019 $377K Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 $190K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.